Prostate cancer is one of the most common cancers in men. Several lines of evidence have suggested that bone morphogenetic protein (BMP) signals play important roles in the generation and progression of prostate cancers. In the present study, we show that BMP-7 inhibits the proliferation of androgen-insensitive PC-3 and DU-145 prostate cancer cells in a medium containing 1% fetal bovine serum, observed as decreased incorporation of , and decreased the activity of Cdk2, leading to hypophosphorylation of Rb proteins. Furthermore, in order to evaluate the impact of BMP signals on prostate tumor growth, we generated the PC-3 cell lines expressing a constitutively active BMP type I receptor (constitutively active (c.a.) activin receptor-like kinase (ALK)-6) in a tetracycline (Tet)-regulated manner. Tet/doxycycline-regulated expression of c.a.ALK-6 resulted in the inhibition of in vitro cell proliferation and reduction of the size of tumors derived from the PC-3 cells subcutaneously injected into immune-deficient mice. Collectively, these findings suggest that BMP signals inhibit growth and proliferation of prostate tumor cells through induction of CDKI. Furthermore, this is the first report of a role for BMP signaling in reducing growth kinetics of androgen-insensitive prostate tumors.
Prostate cancer is one of the most common cancers in men. Several lines of evidence have suggested that bone morphogenetic protein (BMP) signals play important roles in the generation and progression of prostate cancers. In the present study, we show that BMP-7 inhibits the proliferation of androgen-insensitive PC-3 and DU-145 prostate cancer cells in a medium containing 1% fetal bovine serum, observed as decreased incorporation of [ 3 H]thymidine and decreased cell number. Cell cycle analysis by flow cytometry showed an increased fraction of cells in the G1 phase and subsequent decrease in both S and G2/M phase after BMP-7 stimulation. BMP-7 caused an upregulation of the cyclin-dependent kinase inhibitor (CDKI) p21 CIP1/WAF1 , and decreased the activity of Cdk2, leading to hypophosphorylation of Rb proteins. Furthermore, in order to evaluate the impact of BMP signals on prostate tumor growth, we generated the PC-3 cell lines expressing a constitutively active BMP type I receptor (constitutively active (c.a.) activin receptor-like kinase (ALK)-6) in a tetracycline (Tet)-regulated manner. Tet/doxycycline-regulated expression of c.a.ALK-6 resulted in the inhibition of in vitro cell proliferation and reduction of the size of tumors derived from the PC-3 cells subcutaneously injected into immune-deficient mice. Collectively, these findings suggest that BMP signals inhibit growth and proliferation of prostate tumor cells through induction of CDKI. Furthermore, this is the first report of a role for BMP signaling in reducing growth kinetics of androgen-insensitive prostate tumors.
Introduction
Prostate cancer is one of the most common cancers in men and is the second leading cause of male cancer death in the United States (Greenlee et al., 2001) . The mechanisms involved in prostate carcinogenesis remain largely unknown. Growth of prostate carcinoma cells is regulated by a variety of steroid hormones and growth factors.
The transforming growth factor-b (TGF-b) superfamily includes various proteins with similar dimeric structures, for example, activins, Nodal, bone morphogenetic proteins (BMPs), and growth/differentiation factors (Massague, 1998) . BMPs were originally identified as osteoinductive cytokines at extraskeletal sites in vivo (Wozney and Rosen, 1998) . Subsequently, BMPs have been shown to be important during development and in the regulation of various cellular processes such as migration, proliferation, and differentiation of many different cell types, including neuroepithelial and endothelial cells (Kawabata et al., 1998a; Reddi, 1998) .
BMPs signal via three different type I receptors activin receptor-like kinase (ALK)-2, ALK-3 (BMPR-IA), or ALK-6 (BMPR-IB) in complex with the type II receptors BMPR-II or ActR-II. In the presence of BMPR-II, BMP-7 (also called osteogenic protein-1) binds all of the BMP type I receptors, with preference for ALK-2. The receptor-regulated Smads (R-Smads), which act downstream of the BMPRs are Smad1, Smad5, and Smad8. These are phosphorylated by activated type I BMPRs, and enter the cell nucleus together with the common-partner Smad (Co-Smad) 4, resulting in the regulation of various target genes such as Id-1, -2, and Vent-1 (Hogan, 1996) .
Members of the TGF-b superfamily have been shown to inhibit cell proliferation of many different cell types (Massague, 1998) . This is caused by arresting cells late in the G1 phase of the cell cycle. Progression through the cell cycle is a strictly regulated process with several checkpoints. Cyclins D and E in complex with cyclindependent kinase 4 (Cdk4), Cdk6, and Cdk2 modulate the phosphorylation of the retinoblastoma protein (pRb) and thereby control the passage through G1 to S phase (Buchkovich et al., 1989; Weinberg, 1995 , and to downregulate the expression of c-myc, resulting in the inhibition of cell proliferation (Massague et al., 2000) .
BMP-2 and BMP-7 have been reported to elicit both growth stimulatory and inhibitory effects depending on the cell type and differential state of the cells. The growth inhibitory effect of BMP-2 on breast carcinoma cells was mediated by upregulation of the p21
protein, inhibition of Cdk2 kinase activity and hypophosphorylation of pRb (Ghosh-Choudhury et al., 2000a) .
Kim and co-workers performed Western blot and immunohistochemical analyses of BMP receptors in normal, benign, and malignant human prostate samples. The results demonstrated that the normal, benign prostate specimens, and well-differentiated cancers were mostly positive for the expression of BMPR-II, ALK-3, and ALK-6, whereas only one of 10 poorly differentiated prostate cancer cases was positive for each of the three BMPRs (Kim et al., 2000) . These results indicate that human prostate cancer cells frequently exhibit loss of expression of BMPRs and suggest that loss of BMPRs may play an important role during the progression of prostate cancer. Growth of the androgen-sensitive LNCaP cells was inhibited by the addition of BMP-2. For the androgen-insensitive prostate cancer cell lines, PC-3 and DU-145, addition of BMP-2 did not lead to changes in growth in the presence of 10% fetal bovine serum (FBS) (Ide et al., 1997) , although PC-3 cells were shown to transduce BMP signals as monitored by Smad1 phosphorylation (Brubaker et al., 2004) . Thus, the roles of BMPs in the growth of androgeninsensitive prostate carcinoma cells are not fully understood.
In the present study, we show that BMP-7 inhibits the proliferation of PC-3 and DU-145 in a medium containing 1% FBS. An increased fraction of cells in the G1 phase and subsequent decrease in both S and G2/ M phase were observed after BMP-7 stimulation. BMP-7 caused an upregulation of the CDKI p21 CIP1/WAF1 , and decreased the activity of Cdk2. Furthermore, subcutaneous injection of the PC-3 cells into immune-deficient mice revealed that constitutively active ALK-6 reduced the growth of prostate tumors in vivo. These findings suggest that BMP signals reduce growth and proliferation of androgen-insensitive prostate cancer cells both in vitro and in vivo.
Results

Profiles of expression of TGF-b superfamily signaling components in various prostate carcinoma cells
Ide and his co-workers showed that both androgensensitive LNCaP and androgen-insensitive PC-3 cells express type I (ALK-3 and -6) and type II (BMPR-II) receptors for BMPs (Ide et al., 1997) . However, BMPs inhibited the proliferation of LNCaP cells, but not that of PC-3 or DU-145 cells, suggesting that androgeninsensitive prostate carcinoma cells may not express some of the components for BMP signaling pathways. To further evaluate the expression of the TGF-b superfamily signaling components in normal (primary cultured prostate epithelial cells, PrEC) and cancerous (DU-145, PC-3, and LNCaP) prostate cells, we performed reverse transcriptase-polymerase chain reaction (RT-PCR) analysis to detect mRNA transcripts for ligands (BMP-2, -4, -6, -7, TGF-b1 and 3), type I (ALK-1, -2, -3, -4, -5, and -6), type II receptors (BMPR-II, ActR-IIA, ActR-IIB, and TbR-II), and Smads (Smad1, 2, 3, 4, 5, and 8) (Figure 1) .
Transcripts for BMP-2 were present in DU-145, PC-3, and PrEC cells, whereas those for BMP-6 were present in DU-145 and LNCaP cells. Two alternatively spliced forms of BMPR-II mRNA transcripts have been reported (Ishikawa et al., 1995; Liu et al., 1995; Rosenzweig et al., 1995) . As shown in Figure 1 , transcripts for both the wild-type (WT) and short (SH) form of BMPR-II were detected in all types of cells. Interestingly, expression of BMPR-II increased in the absence of androgen. We also detected transcripts for ActR-II in all types of cells. Transcripts for ActR-IIB were detected in DU-145, LNCaP, and PrEC cells, but not in PC-3 cells. Among BMP type I receptors, ALK-2 and ALK-3 were expressed in all types of cells, whereas ALK-6 was expressed only in DU-145, PC-3, and LNCaP cells, but not in PrEC cells. As previously reported (Ide et al., 1997) , ALK-6 expression was downregulated by withdrawal of androgen. The expression of Smads was also examined. We detected mRNA transcripts for R-Smads specific for BMPs (Smad1/5/8) and Co-Smad (Smad4) in all types of the cells. Collectively, these results suggest that all types of prostate cells studied in the present study express transcripts for most components of BMP signaling pathways, suggesting that these cells are capable of responding to BMPs.
The RT-PCR analyses also showed that PrEC, PC-3, and DU-145 cells express receptors and Smads for TGFb. In contrast, LNCaP lacks detectable expression of both TbR-II and Smad3, suggesting that this cell type does not respond to TGF-b (Kim et al., 1996; Guo and Kyprianou, 1998) .
BMP signals are transduced in androgen-insensitive prostate carcinoma cells
The expression profile of BMP signaling components in androgen-insensitive prostate carcinoma cells, DU-145 and PC-3 cells, prompted us to ask whether BMP signals can be transduced in androgen-insensitive DU-145 and PC-3 cells, whose proliferation was not inhibited by BMP in previous reports.
To study the intracellular signaling of BMP-7 in PC-3 cells, we analysed the phosphorylation of RSmad proteins downstream of the BMPRs, that is, Smad1, and Smad5, using an antibody that recognizes phosphorylated forms of these Smad proteins. Stimulation of PC-3 cells for 1 h with 500 ng/ml of BMP-7 in the presence of 1% FBS showed increased phosphorylation of Smad1/5 protein, while stimulation with 5 ng/ml of TGF-b did not induce Smad1/5 phosphorylation ( Figure 2a , lanes 1-3).
To further confirm that BMP signals are transduced in PC-3 cells, we studied the effect of BMP-7 on expression of its target gene, Id-1, in the presence of 1% Previous reports showed that BMP signals do not affect the proliferation of PC-3 cells in the presence of 10% FBS (Ide et al., 1997) . In order to examine the effects of BMP-7 in the presence of 10% FBS, we performed Western blot analyses for phospho-Smad1/5 and Id-1 using PC-3 cells treated with TGF-b or BMP-7 ( Figure 2a and b, lanes 4-6, respectively). While both phosphorylation of Smad1/5 and expression of Id-1 were induced by BMP-7, the levels of induction in the medium containing 10% FBS were less significant than those in the presence of 1% FBS.
BMP-7 causes growth inhibition of androgen-insensitive prostate carcinoma cells
Since BMP signals were shown to be effectively transduced in androgen-insensitive prostate carcinoma cells cultured in the medium containing 1% FBS, we next attempted to examine the effects of BMP-7 on proliferation of androgen-sensitive LNCaP cells and androgen-insensitive PC-3 and DU-145 cells. Ide et al. (1997) showed that BMP-2 inhibits proliferation of LNCaP cells in the presence of synthetic androgen, R1881, while BMP-2 stimulates it in the absence of R1881. When LNCaP cells were treated with different doses of BMP-7 in the absence of R1881, their [ 3 H]thymidine incorporation was stimulated by 20 ng/ ml of BMP-7, which was consistent with a previous report. However, proliferation of LNCaP cells was inhibited by 80 ng/ml and higher concentrations of 3 H]thymidine was not increased by 20 ng/ml of BMP-7 in the presence of R1881. These results suggest that effects of BMP-7 on LNCaP cell proliferation is biphasic in the absence of R1881, that is, stimulatory at lower concentrations and inhibitory at higher concentrations.
Addition of BMP-7 to PC-3 and DU-145 cells in the absence of FBS led to growth inhibition, measured as decreased incorporation of [ 3 H]thymidine in a dosedependent manner (Figure 3a) . When treated with 500 ng/ml of BMP-7, 85 and 65% decrease of [ 3 H]thymidine uptake was observed in PC-3 and DU-145 cells, respectively.
We also studied the dose-dependent effects of BMP-4, -6, and -7 on the [ 3 H]thymidine uptake. Equivalent effects on cell proliferation were observed when PC-3 cells were treated by 80 ng/mg of BMP-4, 200 ng/ml of BMP-6, and 500 ng/ml of BMP-7 (Supplementary Figure S1a) . Moreover, equivalent levels of Smad1/5 phosphorylation were induced by 80 ng/mg of BMP-4, 200 ng/ml of BMP-6, and 500 ng/ml of BMP-7 (Supplementary Figure S1b ). Therefore, we decided to use 500 ng/ml of BMP-7 to further study the effects of BMP signals in androgen-insensitive prostate carcinoma cells.
Cell counting experiments using PC-3 and DU-145 cells also showed that 500 ng/ml of BMP-7 inhibited cell proliferation in the presence of 1% FBS (Figure 3b ). These results suggest that BMP-7 inhibits the proliferation of androgen-insensitive prostate carcinoma cells.
Previously, BMPs were shown to inhibit the proliferation of androgen-sensitive LNCaP cells, while androgen-insensitive PC-3 or DU-145 cells were not affected in the presence of 10% FBS (Ide et al., 1997) . We also found that 500 ng/ml of BMP-7 failed to inhibit the proliferation of PC-3 cells in the presence of 10% FBS (Supplementary Figure S2 , lanes 5 and 6). Taken together, with the finding that BMP-7 did not significantly induce phosphorylation of Smad1/5 in the presence of 10% FBS (Figure 2a) , these results suggest that failure of growth inhibition of androgen-insensitive prostate carcinoma cells by BMP-7 was caused by the 10% FBS used in the experiments.
BMP-7 causes G1 cell cycle arrest of androgen-insensitive prostate carcinoma cells
To further investigate the growth inhibitory action of BMP-7, we analysed the effects of BMP-7 on the cell cycle distribution of PC-3 and DU-145 cells after 24 h of ligand stimulation. The cell cycle distribution was monitored by flow cytometry (FACS) analysis after propidium iodide staining of the cellular DNA. As seen in Figure 4a and b, stimulation of PC-3 and DU-145 cells with BMP-7 increased the fraction of cells in the G1 phase, which was accompanied by decrease of cells in both S and G2/M phases.
We also studied the effects of BMP-7 on the induction of apoptosis in PC-3 cells. Addition of TNF-a and cycloheximide induced apoptosis of PC-3 cells as monitored by DNA fragmentation (Figure 4c ) and activation of caspase-3 activity (Figure 4d ). In contrast, absence of DNA fragmentation ( Figure 4c ) and inability to activate caspase-3 (Figure 4d ) indicate that there was no significant induction of apoptosis of PC-3 cells by BMP-7.
BMP-7 upregulates the expression of the CDKI p21 CIP1/WAF1
Negative regulators of cell proliferation have been shown to increase the expression of CDKIs, resulting , and p27
KIP1
, and by downregulating the expression of c-myc (Massague et al., 2000) . In order to investigate whether BMP-7 also regulates the expression of p15
INK4b , p27 KIP1 , and c-myc, we performed quantitative RT-PCR analyses. As shown in Figure 5c BMP-7 inhibits Cdk2 kinase activity and the phosphorylation of pRb p21 CIP1/WAF1 binds cyclin-dependent kinases (Cdks) to inhibit their activities (Li et al., 1995) . Since BMP-7 increased the level of p21 CIP1/WAF1 proteins in PC-3 cells, we investigated if this also resulted in an altered kinase activity of the Cdk2 protein. PC-3 cells were incubated with or without TGF-b (5 ng/ml) or BMP-7 (500 ng/ml) for 24 h. Total cell lysates were immunoprecipitated with specific Cdk2 antibodies and the kinase activity was measured using a recombinant protein of Histone H1 as a substrate. As shown in Figure 6a , addition of TGF-b or BMP-7 resulted in the inhibition of Cdk2 kinase activity.
pRb protein, a downstream target of the Cdk/cyclin complex, regulates the transition from G1 to S phase of the cell cycle. Cells enter the S phase and proliferate when pRb is hyperphosphorylated, while cells are arrested in G1 when pRb is hypophosphorylated (Buchkovich et al., 1989; Weinberg, 1995) . Treatment of PC-3 prostate carcinoma cells with TGF-b (5 ng/ml) or BMP-7 (500 ng/ml) caused decrease in the amount of hyperphosphorylated pRb protein detected by anti-pRb (Figure 6b , inhibits the activity of Cdk2 to phosphorylate pRb proteins, resulting in a cell cycle arrest in the G1 phase. 
Establishment of tetracycline (Tet)-inducible expression system of constitutively active ALK-6
We have shown that BMP signals inhibit proliferation of androgen-insensitive prostate carcinoma cells in vitro. We next attempted to evaluate the relevance of BMP signals to androgen-insensitive prostate tumor growth in vivo. We chose constitutively active (c.a.) ALK-6 in order to introduce BMP signals because the signaling pathways mediated by ALK-6 were implicated in growth inhibition of prostate carcinoma cells (Ide et al., 1997) . We also attempted to study the effects of c.a.ALK-6 using a Tet-inducible system (Era and Witte, 2000) instead of using stably transfected cell lines in which there may be clonal variation in cell proliferation.
In order to generate parental cell lines (Tet-Parental), a CAG promoter-driven Tet transactivator (tTA) was introduced into PC-3 cells. The expression of c.a.ALK-6 is driven by a Tet-regulated promoter, which is suppressed by the addition of Tet (Tet-off-system). only in the absence of Dox, while parental controls did not express them (Figure 8a ). All tumors appeared encapsulated, exhibited no significant histological differences, and no spontaneous metastasis was detected in any of the animals (data not shown). The expression of c.a.ALK-6, however, reduced the size of resultant tumors by 50% (Figure 8b ), suggesting that BMP signals inhibited androgen-insensitive prostate tumor growth in vivo.
Discussion TGF-b is well known for its growth inhibitory action in a variety of cell types, including malignant prostate cells (Massague et al., 2000; Park et al., 2000) . However, the role of BMPs on cell growth is still largely unknown. In the present study, we show an antiproliferative effect of BMP-7 on human androgen-insensitive prostate carcinoma cell lines in the presence of 1% FBS. Stimulation with BMP-7 increased the expression of CDKI p21 CIP1/WAF1 protein, leading to hypophosphorylation of pRb and G1 cell cycle arrest. CDKI has also been shown to be upregulated after BMP treatment of smooth muscle cells (Wong et al., 2003) . In human thyroid carcinoma cells, BMP-7 inhibited cell proliferation via induction of the expression of p21 CIP1/WAF1 and p27 KIP1 (Franzen and Heldin, 2001 ). These results are consistent with the present data concerning the effect of BMP-7 on p21 CIP1/WAF1 in prostate carcinoma cell growth.
We showed that expression of c.a.ALK-6 reduced the size of tumors derived from subcutaneously injected PC-3 cells (Figure 8b ), suggesting that BMP signals inhibited androgen-insensitive prostate tumor growth in vivo. In vivo tumor growth involves complex processes including cell proliferation and angiogenesis. While the inhibitory effects of BMP signals on prostate carcinoma cells have been shown, we need to elucidate the effects of BMP signals on various steps of in vivo tumor growth using the PC-3 cells with Tet-regulated expression of c.a.ALK-6.
Previous reports showed that growth of androgeninsensitive prostate carcinoma cells was not affected by BMPs in the presence of 10% FBS (Ide et al., 1997) . We also found that BMP-7 failed to inhibit cell growth of PC-3 cells in the presence of 10% FBS (Supplementary Figure S2a, lanes 5 and 6) . In the presence of 10% FBS, BMP-7 did not induce phosphorylation of Smad1/5 (Figure 2a) or expression of Id-1 ( Figure S2b ) as efficiently as in the presence of 1% FBS, suggesting that FBS may contain antagonists of BMP signals, such as Noggin and chordin, or induce their expression. When Noggin was added to the culture containing 1% FBS, BMP-7 failed to inhibit proliferation of PC-3 cells and to phosphorylate Smad1/5 (data not shown).
TGF-b and activin transduce their signals through a set of R-Smads (Smad2/3), which competes with the other set of BMP specific R-Smads (Smad1/5/8) for CoSmad (Candia et al., 1997) , and induce the expression of inhibitory Smads (Smad6/7), both of which inhibit BMP signals (Miyazono, 2000) . In order to examine whether TGF-b/activin signals are involved in the inhibition of BMP signals in androgen-insensitive prostate carcinoma cells cultured in the presence of 10% FBS, we utilized SB-431542, a synthetic compound that specifically inhibits the kinases of type I receptors for TGF-b/ activin (ALK-4, ALK-5, and ALK-7) Inman et al., 2002) . However, as shown in Figure S2 , inhibition of TGF-b/activin signals by SB-431542 did not lead to growth inhibition or induction of Id-1 expression by BMP-7 in PC-3 cells cultured in the presence of 10% FBS, suggesting that TGF-b/activin signals are not involved in the serum-derived inhibition of BMP signals.
The most favored site of prostate cancer metastasis is bone, where BMPs are abundant (Scher and Yagoda, 1987; Clarke et al., 1991) . In addition, expression of BMPs has been detected in prostate skeletal metastasis (Autzen et al., 1998; Thomas et al., 1998; Masuda et al., 2003) . Since the present study showed that BMP signals are capable of inhibiting the growth of aggressive androgen-insensitive cells in vitro and in vivo, elucidation of such BMP antagonists present in bone may provide useful therapeutic strategies to introduce growth inhibitory BMP signals to prostate cancer that are metastasized to bone.
Material and methods
Cell culture
PrECs were obtained from Clonetics (Walkersville, MD, USA), and were maintained in PrEBM (Clonetics). LNCaP, PC-3, and DU-145 cells were maintained in RPMI-1640 (Sigma, St Louis, MO, USA), HAM's-F12 (IWAKI, Tokyo, Japan), MEM (Sigma) containing 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin, respectively. TGF-b3 and BMP-7 were obtained from R&D Systems (Minneapolis, MN, USA).
RT-PCR analysis
Total RNA was isolated from various cells with ISOGEN (NipponGene, Tokyo, Japan), and first-strand cDNA was synthesized using the Superscript First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA) with random hexamer primers. The expression of various signaling components was compared by semiquantitative RT-PCR analysis. A human b-actin primer set was used to normalize the amount of total cDNA in each sample. PCR products were separated by electrophoresis in agarose gel (1%) and visualized with ethidium bromide. As a control, a PCR reaction for each set of primers was run against H 2 O. Quantitative real-time RT-PCR analysis was performed using the GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) as described (Ota et al., 2002) . The primer sequences and expected sizes of PCR products are available online as indicated in Supplementary Table 1 .
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were performed as described (Kawabata et al., 1998b) . Antiphospho-Smad1/5 and anti-Smad1 antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively. Anti-p21 CIP1/WAF1 antibody was obtained from Oncogene Research Products (San Diego, CA, USA). Anti-a-tubulin (T9026) antibody, antipRb antibody, and anti-ppRb (807/811S) antibody were purchased from Sigma Aldrich (St Louis, MO, USA), BD Biosciences (San Jose, CA, USA), and Cell Signaling Technology (Beverly, MA, USA), respectively. Anti-Id-1 antibody was from Santa Cruz Biotechnology. Anti-HA antibody (3F10) was obtained from Roche (Indianapolis, IN, USA).
Cell proliferation assay
To explore the effects of ligands, cells were seeded at a density of 7.5 Â 10 3 cells/well in six-well plates and starved (1% FBS) for 24 h before ligand stimulation. Cells were trypsinized and counted by a Coulter counter on days 2 and 4 after ligand stimulation. The experiments were performed in triplicate.
Thymidine incorporation assay
Cells were seeded at a density of 2 Â 10 4 cells/well in 24-well plates and cultured overnight. The serum concentration in the medium was then decreased to 0%, and the cells were incubated for another 24 h, followed by stimulation with various ligands. At 24 h after stimulation, the cells were labeled with [ 3 H]thymidine for 4 h. Thymidine incorporation into the TCA-insoluble fraction was analysed as described previously (Ebisawa et al., 1999) .
DNA ladder formation assay
Nuclear DNA from cells treated with TNF-a (50 ng/ml) and cycloheximide (2 mM) for 24 h or BMP-7 (500 ng/ml) for 24 h was extracted using 20 mM Tris-HCl (pH 7.5), 10 mM EDTA, and 0.5% Triton X-100. The resulting lysate was centrifuged for 5 min at 15 000 r.p.m. The supernatant was treated with RNase and proteinase K, followed by isopropanol precipitation. DNA was separated by electrophoresis in an agarose gel (2%). After electrophoresis, the gel was stained with ethidium bromide and the DNA was visualized under UV light.
Caspase activity assay
Caspase-3 activity was determined using the CPP32/Caspase-3 Colorimetric Protease Assay Kit (MBL, Nagoya, Japan) according to the manufacturer's protocol. In brief, 1 Â 10 6 cells were lysed in 150 ml of chilled cell lysis buffer, and total cell lysates (100 mg) were incubated with 4 mM DEVD-pNA substrate (200 mM final concentration) at 371C for 1 h. Caspase-3 activity was measured by colorimetric reaction at 405 nm.
Cell cycle analysis
PC-3 cells and DU-145 cells were grown in medium with 1% FBS and stimulated with 500 ng/ml BMP-7 for 24 h. All cells (attached and detached) were collected, washed once in PBS, and the cellular DNA was stained with propidium iodide according to the method described (Vindelov et al., 1983) . The cellular DNA content was analysed by FACS (Beckman Coulter, Fullerton, CA, USA).
Measurement of Cdk kinase activity
PC-3 cells were stimulated with 500 ng/ml BMP-7 for 24 h and lysed on ice for 30 min in TNE buffer (50 mM Tris-HCl (pH 8.0), 1% NP-40, 1 mM EDTA, 150 mM NaCl, 0.5 mM dithiothreitol (DTT), and 1.4 mg/ml aprotinin) and centrifuged to remove debris. The supernatant was subjected to immunoprecipitation by adding 500 ng of Cdk2 antibodies (Santa Cruz Biotechnology) and 20 ml of protein G-Sepharose (Amersham Pharmacia Biotech, Orsay, France). Immunoprecipitates were incubated with kinase buffer (20 mM HEPES (pH 7.5), 20 mM MgCl 2 , 20mM b-glycerophosphate, 2 mM DTT, 100 mM Na 3 VO 4 , and 0.5 mM NaF) consisting of 5 mCi of [g-32 P]ATP (3000 Ci/mmol; Amersham Pharmacia Biotech), 1 mg Histone H1 (Roche), and incubated at 371C for 20 min. The samples were subjected to SDS-PAGE. Phosphorylated Histone H1 proteins were visualized using a Fuji BAS 1800 Bio-Image Analyzer (Fuji Photo Film, Tokyo, Japan).
Establishment of Tet-inducible system
The Tet-regulatory system was used to obtain c.a.ALK-6-regulatable PC-3 clones. To establish a reliable parental PC-3 cell line expressing tTA (Baron et al., 1997) , tTA expression vectors pCAG 20-1 (Niwa et al., 1991; Era and Witte, 2000) and pUHD10-3 Puro (Era and Witte, 2000) were transfected into PC-3 cells using Fugene6 (Roche), and cells were grown with 1 mg/ml puromycin in Tet-free medium. Six parental clones proliferating in Tet-free medium, but dying in the presence of Tet, were selected as primary parental Tetregulatory PC-3 cells. The Tet-regulatable c.a.ALK-6 construct, pUHD 10-3 c.a.ALK-6 IRES GFP, was generated by inserting c.a.ALK-6 into EcoRI and XbaI sites in pUHD10-3 IRES EGFP vector (Era and Witte, 2000) . Two parental PC-3 clones were transfected with pUHD 10-3 c.a.ALK-6 IRES GFP vector and neomycin plasmid, pMC1NEO (Stratagene, La Jolla, CA, USA). The cells were maintained in the presence of 1 mg/ml Tet and 400 mg/ml G418. Multiple neomycinresistant colonies from each parental clone were picked and clones tightly regulated by Tet were initially analysed for GFP expression by FACS (Beckman Coulter, Fullerton, CA, USA). The GFP expressing clones were subsequently examined for c.a.ALK-6 expression by Western blotting in Tet þ and TetÀ conditions. Finally, a total of 11 Tet-regulatable c.a.ALK-6 clones were obtained.
Mouse subcutaneous injection and analysis
Male Balb/c nu/nu mice (10 animals per condition) were injected subcutaneously in each flank with 1 Â 10 6 tumor cells suspended at 5 Â 10 6 cells/ml in Matrigel (BD Biosciences). After 35 days, mice were killed, and tumors were dissected and weighed. Experiments were performed three times and the data are presented as mean7standard error (s.e.). Statistical analyses were performed using Student's t-test and the different levels of significance are indicated in the figure. All experimental protocols were conducted in accordance with the policies of the Animal Ethics Committee at the University of Tokyo.
Abbreviations ALK, activin receptor-like kinase; BMP, bone morphogenetic protein; c.a., constitutively active; Co-Smad, common-partner Smad; Dox, doxycycline; FBS, fetal bovine serum; R-Smad, receptor-regulated Smad; Tet, tetracycline; TGF, transforming growth factor; tTA, tetracycline transactivator.
